Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T
First Dept. of Surgery, Kyoto University.
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 1):1421-7.
In the present study we tried to reevaluate the optimal combination timing in the experimental treatment with BRM and chemotherapeutic agents. BALB/c mice with advanced malignant ascites tumor (MOPC 104 E) were treated with cyclophosphamide (CPA, 2 mg/kg) and BRM such as immunostimulator (OK-432, Lentinan or Bestatin), interleukin-2 (IL 2) or cultured killer cells. The survival of mice was prolonged when immunostimulators were given before CPA. However, no combined effect was seen when immunostimulators were administered after CPA. Treatment with cultured killer cells and in vivo IL 2 after immunochemotherapy (immunostimulator followed by CPA) was the most effective protocol in which immunostimulator, chemotherapy, killer cells and IL 2 respectively seemed to induce, regulate, supplement and amplify anti-tumor effector cells.
在本研究中，我们试图重新评估生物反应调节剂（BRM）与化疗药物联合进行实验性治疗时的最佳组合时机。对患有晚期恶性腹水肿瘤（MOPC 104 E）的BALB/c小鼠，用环磷酰胺（CPA，2 mg/kg）和BRM进行治疗，如免疫刺激剂（OK-432、香菇多糖或贝司他汀）、白细胞介素-2（IL-2）或培养的杀伤细胞。当在CPA之前给予免疫刺激剂时，小鼠的生存期延长。然而，当在CPA之后给予免疫刺激剂时，未观察到联合效应。免疫化疗（免疫刺激剂后接CPA）后用培养的杀伤细胞和体内IL-2进行治疗是最有效的方案，其中免疫刺激剂、化疗、杀伤细胞和IL-2似乎分别诱导、调节、补充和放大抗肿瘤效应细胞。
